Viamet is a clinical-stage infectious disease company that discovers and develops novel, small molecule therapies for the treatment of human fungal infections.

from http://www.viamet.com/

Research Grants 5 show all


$130K
2012

$145K
2013

$242K
2014

$373K
2015

$95K
2016

Patents 341show all

  • 108
    C07D - Heterocyclic compounds
  • 81
    A01N - Preservation of bodies of humans or animals or plants or parts thereof
  • 80
    A61K - Preparations for medical, dental, or toilet purposes
  • 9
    Y02A - Technologies for adaptation to climate change
  • 6
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 5
    C07B - General methods of organic chemistry
  • 5
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 2
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Clinical Trials 3show all

2Phase 21N/A

SEC Filings show all


4
D

1
S-1

Contact Information

Durham, NC
United States

SEC Form D Funding Events

DateOfferedSoldType
2014-03-12$15,000,000$10,000,000Equity, Option to Acquire, Security to be Acquired
2013-06-17$15,000,000$10,000,000Equity, Option to Acquire, Security to be Acquired
2012-01-17$39,600,000$39,600,000Equity

Key Executives

  • Robert J. Schotzinger, M.D., Ph.D.
    Executive Officer, Director
  • James Rosen
    Director
  • Douglas Reed
    Director
  • William T. White III
    Director
  • Lauren Silverman
    Director
  • S. Edward Torres
    Director
  • Andrew von Eschenbach
    Director
  • Neil Moore
    Executive Officer
  • Richard Katz
    Executive Officer
  • Kenneth Bahk
    Director